HT for Preventing Chronic Conditions in Postmenopausal Women: USPSTF Weighs in Again

Task force remains against use of hormone therapy for primary prevention of chronic conditions.

Sponsoring Organization: U.S. Preventive Services Task Force (USPSTF)

Target Population: OB/GYN and primary care providers

Background and Objective

In updating its 2012 recommendations, the USPSTF reviewed evidence from randomized clinical trials (RCTs) on the benefits and harms of hormone therapy (HT). The task force determined that small to moderate benefits (prevention of osteoporotic fractures, diabetes, and colorectal cancer) as well as harms (excess risk for invasive breast cancer, coronary heart disease, thromboembolism, stroke, dementia, gallbladder disease, and urinary incontinence) result from use of HT.

Key Recommendations

HT has no net benefit for primary prevention of chronic conditions in most menopausal women (D recommendation).
Th…

Reviewing Author

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health